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Abstract Mutations in the FBN1 gene are the major
cause of Marfan syndrome (MFS), an autosomal dominant
connective tissue disorder, which displays variable mani-
festations in the cardiovascular, ocular, and skeletal sys-
tems. Current molecular genetic testing of FBN1 may miss
mutations in the promoter region or in other noncoding
sequences as well as partial or complete gene deletions and
duplications. In this study, we tested for copy number vari-
ations by successively applying multiplex ligation-depen-
dent probe ampliWcation (MLPA) and the AVymetrix
Human Mapping 500 K Array Set, which contains probes
for »500,000 single-nucleotide polymorphisms (SNPs)
across the genome. By analyzing genomic DNA of 101
unrelated individuals with MFS or related phenotypes in
whom standard genetic testing detected no mutation, we
identiWed FBN1 deletions in two patients with MFS. Our
high-resolution approach narrowed down the deletion
breakpoints. Subsequent sequencing of the junctional
fragments revealed the deletion sizes of 26,887 and
302,580 bp, respectively. Surprisingly, both deletions aVect
the putative regulatory and promoter region of the FBN1
gene, strongly indicating that they abolish transcription of
the deleted allele. This expectation of complete loss of
function of one allele, i.e. true haploinsuYciency, was con-
Wrmed by transcript analyses. Our Wndings not only empha-
size the importance of screening for large genomic
rearrangements in comprehensive genetic testing of FBN1
but, importantly, also extend the molecular etiology of
MFS by providing hitherto unreported evidence that true
haploinsuYciency is suYcient to cause MFS.
Introduction
Marfan syndrome (MFS; MIM# 154700) is a prevalent con-
nective tissue disorder with variable manifestations in the
skeletal, ocular, and cardiovascular systems (De Paepe et al.
1996). MFS is inherited in an autosomal dominant manner
and caused by mutations in the gene encoding the 350-kD
extracellular matrix protein Wbrillin-1 (FBN1; MIM#
134797) in the majority of cases (Dietz et al. 1991).
Recently, heterozygous mutations in the genes coding for
transforming growth factor beta receptors I (TGFBR1;
MIM# 190181) and II (TGFBR2; MIM# 190182) have also
been reported in patients with MFS-related disorders, such
as MFS type 2 (MFS2; MIM# 154705), Loeys-Dietz aortic
aneurysm syndrome (LDS; MIM# 609192), and familial
thoracic aortic aneurysms and dissections (TAAD; MIM#
132900), indicating genetic heterogeneity in MFS and its
related conditions (Mizuguchi et al. 2004; Loeys et al. 2005;
Pannu et al. 2005; Mátyás et al. 2006; Loeys et al. 2006).
In classical MFS patients, mutation analyses have failed
to detect FBN1 involvement in at least 10% of cases,
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suggesting not only that the disease-causing mutation
occurs in a diVerent gene but also demonstrate the limita-
tions of commonly used standard PCR-based screening
approaches. Indeed, current molecular genetic testing of
FBN1, although powerful, may miss mutations in the pro-
moter region or in other noncoding sequences as well as
deletions/duplications of the entire gene or part of it.
Accordingly, in the locus-speciWc mutation databases more
than 600 unique FBN1 mutations but only 12 (2.0%) large
deletions have been registered (UMD, http://www.umd.
be:2030; HGMD, http://www.hgmd.cf.ac.uk/ac/gene.php?
gene = FBN1). In contrast, the relative frequency of large
deletions available in the Human Gene Mutation Database
(http://www.hgmd.cf.ac.uk) containing 64,251 mutations in
2,362 genes (version 09/12/2006) is signiWcantly higher
(5.6%), suggesting that more large FBN1 deletions await
detection.
In this study, we tested this hypothesis by applying the
recently introduced multiplex ligation-dependent probe
ampliWcation (MLPA) technique, which is suitable for the
identiWcation of large deletions and less laborious than
methods traditionally used for detection of gross rearrange-
ments, such as Southern blot and cytogenetic techniques.
MLPA relies on sequence-speciWc probe hybridization to
genomic DNA, followed by ampliWcation of the hybridized
probe with universal primers, and semi-quantitative analy-
sis of the resulting PCR products (Schouten et al. 2002).
Here, we report on large deletions aVecting the 5 region of
the FBN1 gene in two unrelated MFS patients. The break-
points of the deletions identiWed by MLPA were narrowed
down by means of high-density single-nucleotide polymor-
phism (SNP) arrays and characterized by using long-range
PCR, subsequent cycle sequencing, and transcript analyses.
Our data provide hitherto unreported evidence for true hap-
loinsuYciency in patients with MFS.
Subjects and methods
Patients
A cohort of 101 unrelated patients with suspected MFS
(»40%) or MFS-like phenotypes (»60%) involving mono-
symptomatically or predominantly the cardiovascular
(»39%), skeletal (»18%) or ocular (»3%) system was
selected for this study. In this cohort, previous denaturing
high-performance liquid chromatography (DHPLC) analy-
sis and/or sequencing of all exons and Xanking intronic
regions of FBN1, TGFBR1, and TGFBR2 revealed no dis-
ease-causing sequence variant (Mátyás et al. 2002a, 2006).
Data on the clinical phenotypes of patients were collected
from medical records or during physical examinations by
one of the authors (B.S, T.C.).
Multiplex ligation-dependent probe ampliWcation (MLPA)
A total of 100 ng of genomic DNA of each patient was
screened by MLPA using the SALSA kits P065 (probes for
FBN1 and TGFBR2), P066 (probes for FBN1), and P148
(probes for both TGFBR1 and TGFBR2), commercially
available from MRC-Holland (Amsterdam, The Nether-
lands), on an ABI PRISM 310 or 3100 Genetic Analyzer
(Applied Biosystems, Rotkreuz, Switzerland) according to
the manufacturers’ instructions. Each MLPA signal was
normalized and compared to the corresponding peak area
obtained in a control DNA sample. Deviations more than
30% were suspected as alterations and veriWed by repeated
MLPA analysis.
High-density microarray analyses
In order to narrow down the breakpoints of the deletions
identiWed by MLPA, we used the high-density GeneChip
Human Mapping 500 K Array Set (AVymetrix, Santa Clara,
CA, USA), which contains »500,000 genomewide SNPs,
according to the manufacturer’s manual. After hybridiza-
tion and scanning, raw data were processed using the
GCOS 1.4 software (AVymetrix, Santa Clara, CA, USA)
and probe cell intensities were calculated and summarized
for the respective probe sets by means of the MAS5 algo-
rithm (Hubbell et al. 2002). SNP allele calls, marker inten-
sity values, and quality control measures were computed by
the GTYPE software (AVymetrix, Santa Clara, CA, USA)
using the integrated RLMM algorithm (Rabbee and Speed
2006). Quality control measures were considered before
performing the statistical analysis, including appropriate
numbers of present calls (>97%) and control SNP perfor-
mance (ModiWed Partitioning Around Medoids [MPAM]
algorithm Call Rate [MCR] close to or higher than 90%).
For the determination of regions with loss of heterozygosity
and decreased signal intensity, advanced data analyses were
performed using the academic software tools dChip
(Harvard University; http://www.biosun1.harvard.edu/
complab/dchip) and CNAG2.0 (University of Tokyo; http://
www.genome.umin.jp).
AmpliWcation and sequencing of the junctional fragments
Primers Xanking the predicted deletions were designed
based on decreased MLPA and array signal intensities and
were used in long-range PCR (44F 5-ACGAACCTTTCA
AATATTCCCCC-3, 44R 5-TGGGAGTGATGGGACA
ACTGAG-3, 70F 5-ACTGCTGCAGAGTGCCTGATA-3,
70R 5-GGGCTATGTGCTCTGGCTATT-3). BrieXy,
100 ng of DNA and BuVer 3 were used with the Expand
Long Template PCR System (Roche Diagnostics, Rotkreuz,
Switzerland) according to the manufacturer’s instructions
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with the following cycling proWle: 5 min initial denatur-
ation at 92°C; 10 cycles of 10 s at 92°C, 30 s at 58.5°C (for
44F/44R) or 59.3°C (for 70F/70R), and 8 min at 68°C; fol-
lowed by 25 cycles of 15 s at 92°C, 30 s at 58.5°C (for 44F/
44R) or 59.3°C (for 70F/70R), and 8 min (+20 s/cycle) at
68°C; Wnished by a 7 min Wnal extension step at 68°C.
Amplicons were treated with ExoSAP-IT (USB Corpora-
tion, Cleveland, OH, USA) and sequenced using internal
primers by means of a BigDye Terminator Cycle Sequenc-
ing Ready Reaction kit v1.1 on an ABI PRISM 3100
Genetic Analyzer (Applied Biosystems, Rotkreuz, Switzer-
land). Sequences were analyzed using SeqScape 2.5
(Applied Biosystems, Rotkreuz, Switzerland) and the
genome browser of the University of California, Santa Cruz
(UCSC; http://www.genome.ucsc.edu). Sequence variants
were referenced with respect to the human genome reference
sequence (NCBI build 36.1, March 2006) according to the
guidelines of the HGVS (http://www.hgvs.org/mutnomen).
Transcript analyses
Primary Wbroblasts were available only from Patient 70.
Total RNA was isolated by the RNeasy mini kit (Qiagen,
Hilden, Germany) from cultured Wbroblasts. Prior to RNA
extraction, Wbroblasts were incubated with 10 g/ml cyclo-
heximide (Actidione; Sigma, St. Louis, MO, USA) for 15 h
in order to inhibit potential nonsense-mediated mRNA
decay. Reverse transcription (RT)-PCR was used to amplify
a complementary DNA (cDNA) fragment (1,484 bp) con-
taining the polymorphism c.8,930C > T (rs1042078, aver-
age heterozygosity 0.490 § 0.071, dbSNP build 126) that is
located in the 3 untranslated region (UTR) of the FBN1
gene and was detected during the mutation screening at
genomic DNA level. RT-PCR was performed by means of
the OneStep RT-PCR kit (Qiagen, Hilden, Germany) using
125 ng RNA and primers speciWc to the FBN1 exons 63
(5-AGGGCGGTTACCTGTGTG-3) and 65 (5-CCCCT
TGTTGACAGGAATGAC-3). RT-PCR product was
sequenced by using an internal primer in exon 65 (5-AGC
ACCATTACAAACCCTCACA-3) as described above.
The presence of allele-speciWc transcripts was considered
according to the procedure previously outlined (Mátyás
et al. 2002b; Qiu et al. 2003).
Results
Multiplex ligation-dependent probe ampliWcation (MLPA)
In 2 out of 101 previously “mutation-negative” patients
with MFS or related phenotypes, MLPA analyses resulted
in abnormal patterns. In Patient 44, MLPA revealed
reduced relative peak areas for both probes of FBN1 exon 1
(Fig. 1), suggesting the deletion of this exon. Only the
father’s DNA was available for MLPA analysis, which
revealed a normal proWle (data not shown). In Patient 70,
MLPA showed reduced relative peak areas of fragments
corresponding to exons 1–9 and 12–16 (Fig. 1), suggesting
the deletion of exons 1–16. The parents of Patient 70 were
not available for testing. All other patients showed relative
peak areas within the range deWned as normal. MLPA for
the TGFBR1 and TGFBR2 genes (kit P148) showed normal
relative peak areas in all patients (data not shown). Taken
together, the relative frequency of gross FBN1 deletions in
patients with suspected MFS in whom exon-by-exon
screening revealed no mutation in the genes FBN1,
TGFBR1, and TGFBR2 can be estimated as 2/101 (0.3–
7.7%, P = 0.05; according to VassarStats, http://www.fac-
ulty.vassar.edu/lowry/prop1.html). Patients 44 and 70 were
sporadic cases and fulWlled the diagnostic criteria of Ghent
nosology (Table 1).
IdentiWcation and characterization of breakpoints
Loss of heterozygosity and decreased signal intensities upon
high-density SNP array analyses conWrmed the MLPA
results and narrowed down the deletion breakpoints. In
Patient 44, loss of heterozygosity occurred in a region span-
ning 94.5 kb between the SNPs rs1678982 and rs784408,
while reduction of signal intensities indicated a deletion of
less than 44.4 kb between rs2018854 and rs931781
(Fig. 2a). Similarly, in Patient 70 the deletion was localized
to a region of »317 kb between rs11070644 and rs2899422
by considering decreased array signal intensities (Fig. 3a).
Based on these data, forward and reverse primers were
designed for long-range PCR, which resulted in fragments
of »6.5 and »8.5 kb in Patient 44 and Patient 70, respec-
tively. Due to the size of normal alleles (33.2 kb using
primers 44F/44R and 311.3 kb with primers 70F/70R),
ampliWcations were observed from the deleted alleles only,
but not from the normal alleles of either Patient 44, his
father, Patient 70, or several controls (data not shown).
Subsequent sequencing of the long-range PCR products
identiWed a deletion of 26,887 bp in Patient 44 and
302,580 bp in Patient 70 (Figs. 2b, 3b).
Transcript analyses
Both deletions aVect exon 1 (345 bp), which contains the
translation initiation ATG codon at nucleotide positions
182–184, and a »4-kb upstream region of the FBN1 gene,
which may harbor the promoter, thus strongly indicating
that they abolish the transcription/translation of the respec-
tive deleted allele (Figs. 2, 3). This expectation of complete
loss of function of one allele (true haploinsuYciency) was
conWrmed by RT-PCR sequence analysis in Patient 70 being
26 Hum Genet (2007) 122:23–32
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heterozygous for the c.8,930C > T polymorphism in the
FBN1 3UTR, which showed the transcription of only one
allele (Fig. 4). Appropriate clinical samples were not avail-
able from Patient 44 to verify this Wnding in aVected tissue.
Discussion
In this study, we applied for the Wrst time MLPA and high-
density SNP arrays to analyze genomic DNA samples of
patients with MFS or related phenotypes in whom standard
molecular testing detected no mutation. Our results contrib-
ute to the molecular etiology of MFS by providing pre-
viously unprecedented evidence for true haploinsuYciency
in patients. Our data signiWcantly extend the number of
large FBN1 deletions, which have previously been detected
by cDNA or Southern blot analyses (Table 2), demonstrat-
ing that comprehensive genetic testing of FBN1 should
include screening for large genomic rearrangements by
using an appropriate method.
The P065-P066 MLPA kit used in this study contains
probes for 53 of the 65 FBN1 exons. Since not all FBN1
Fig. 1 Results of semiquantitative MLPA analyses in Patients 44 and
70. The normal range of normalized relative peak areas (white bars) is
given by dotted lines (§0.30). Values out of this range are marked by
black bars and numbers of the corresponding FBN1 exons (Ex). a Nor-
malized relative peak areas measured with the P065 kit, which consists
of 25 MLPA probes for FBN1 and eleven control MLPA probes located
on chromosomes 1, 2, 4, 5, 8, 11, and 16 (fragments 1, 2, 6, 13, 19, 25,
31, 32, 36, 40, and 43) as well as probes for all seven TGFBR2 exons
(fragments 8, 12, 16, 20, 24, 28, and 34). b Normalized relative peak
areas measured with the P066 kit, which consists of MLPA probes for
30 FBN1 exons, in two of which (exons 1 and 6) a probe of P065 is lo-
cated as well, and eleven control MLPA probes located on chromo-
somes 1, 3, 5, 6, 13, 16, and 22 (fragments 1, 2, 7, 12, 17, 22, 27, 31,
36, 40, and 41). Taken together the results of the P065 and P066 kits,
MLPA revealed reduced relative peak areas of fragments correspond-
ing to the FBN1 exon 1 in Patient 44 and to the FBN1 exons 1–9 and
12–16 in Patient 70 (note that there are no MLPA probes for the FBN1
exons 10 and 11 as well as 20, 22, 27 32, 37, 39, 48, 51, 59, and 61)
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exons were analyzed, a deletion or duplication of non-tested
exons cannot be excluded. Furthermore, copy-number neu-
tral rearrangements as well as those aVecting no MLPA-spe-
ciWc sequences could not be detected because such
mutations do not change the relative peak area of MLPA
probes. In contrast to traditionally used techniques, MLPA is
a simple method to detect gross deletions. However,
sequence variations in the probe-binding regions as well as
probe and DNA quality may signiWcantly aVect MLPA
results. Accordingly, it is highly recommended to conWrm
MLPA results by an independent method. Both deletions
described here were also detectable by quantitative real-time
PCR (data not shown). Like MLPA, the Mapping 500 K
Array Set cannot detect balanced rearrangements and is sen-
sitive to handling and DNA quality in our experience. Dele-
tions that aVect only a small proportion of templates
(mosaicism) would also be expected to present detection
problems for both MLPA and SNP array technologies.
The deletions presented here generated junction frag-
ments with short stretches of identical sequences at the sites
of breakpoints (Figs. 2b, 3b), a phenomenon that has been
described not only in FBN1 but also in other genes (Giac-
alone and Francke 1992; Otto et al. 2000; Liu et al. 2001).
The precise mechanism of this phenomenon, however,
remains to be elucidated. Both deletions comprise exon 1
and a »4-kb upstream region of FBN1, a surprising Wnding
not reported before, which is most likely due to the limita-
tions of previously used screening methods. A priori, one
might expect that these deletions aVect the regulatory or
promoter regions of FBN1. Indeed, both deleted regions
include the three alternatively spliced exons of the FBN1
gene (C, A, and B; Fig. 2a), which are thought to have reg-
ulatory function (Corson et al. 1993; Biery et al. 1999).
Furthermore, although little is known about the FBN1 pro-
moter region, very recent studies indicates that the FBN1
gene is controlled by a single promoter with a start site
located up to 500 bases upstream (5) of the ATG start
codon (11th International Congress of Human Genetics,
http://www.ichg2006.com/abstract/488.htm), which is
aVected by both deletions as well.
In general, no transcript will be produced when the
promoter is deleted, unless alternative down- or up-stream
Table 1 Clinical proWles of pa-
tients carrying a large deletion 
identiWed in this study
Organ systems Criteriaa Patient 44 Patient 70
Skeletal Major criteria
Pectus carinatum ¡ +
Reduced upper-segment to lower-segment ratio 
or arm span to height ratio >1.05
+ +
Wrist and thumb signs + +
Scoliosis of >20° + ¡
Reduced extension at the elbows (<170°) + +
Minor criteria
Pectus excavatum of moderate severity (asymmetric) + ¡
Joint hypermobility + ¡
Highly arched palate with crowding of teeth + +
Facial appearance (retrognathia, malar hypoplasia, 
down-slanting palpebral Wssures)
+ +
Nonfamilial overgrowth + +
Ocular Major criterion
Ectopia lentis ¡ ¡
Minor criterion
High myopia + +
Cardiovascular Major criterion
Dilatation of the ascending aorta + +
Minor criterion
Mitral valve prolapse with mitral valve regurgitation + +
Skin and integument Minor criterion
Striae distensae without obvious cause + ¡
Pulmonary NI NI
Dura NP NP
Family history NI NI
+ Present; ¡ absent; NP not per-
formed; NI system not involved
a Only criteria present in one 
of the patients are listed (except 
major criterion in the ocular 
system)
28 Hum Genet (2007) 122:23–32
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promoter is activated. The latter occurs when a deletion
fuses two genes that are in the same transcriptional orienta-
tion. Since the deletion in Patient 70 involves also the
neighboring CEP152 gene, which encodes the centrosomal
protein of 152 kDa with unknown function (Fig. 3a), we
made use of a polymorphism in the FBN1 3UTR to deter-
mine whether or not both alleles are transcribed. In Patient
70, sequence analysis of RT-PCR products revealed tran-
scripts from only one allele (Fig. 4). This Wnding is consis-
tent with the expectation that the deletion involves the
regulatory and promoter regions and thus prevents tran-
scription. The impact of the partial deletion of CEP152, if
any, is unknown. In Patient 44, the activation of an alterna-
tive cryptic promoter, e.g. downstream of the deletion in
intron 1 of FBN1, could not be excluded. The quantiWcation
of the total amount of FBN1 transcripts was not within the
scope of this study, but, similar to other modifying factors,
diVerences in normal FBN1 expression may explain some
of the clinical variability seen in Patients 44 and 70
(Table 1), as previously demonstrated in a family with MFS
(Hutchinson et al. 2003). Although, except of the father of
Patient 44, neither the parents nor other family members
(with no hints for MFS by history) were available for
genetic testing, negative family histories suggest de novo
occurrence of the deletions.
Interestingly, neither Patient 44 nor Patient 70 presents
any sign of ectopia lentis. This is in accordance with the
observation that MFS patients with a premature termination
codon (PTC) mutation, which can lead to functional hap-
loinsuYciency, i.e., preferential degradation of mutant tran-
scripts due to nonsense-mediated mRNA decay (NMD),
have a distinctly lesser chance of developing ectopia lentis
than individuals with FBN1 cysteine substitutions (Schrij-
ver et al. 2002; Rommel et al. 2005). However, the clinical
Wndings in Patients 44 and 70 could also be explained by
the lack of ocular involvement seen in about one third of
Fig. 2 Breakpoint analyses in Patient 44. a Schematic representation
of the genome in the region of deletion as well as an overview of the
results of the MLPA and SNP array analyses. The open arrow below
the gene name indicates the direction of transcription. Exons are spec-
iWed by bars and marked with the corresponding number or character
(cf. C, A, and B are alternatively spliced exons of FBN1, while exon 1,
also known as exon M, harbors the presumptive translation initiation
codon). The region with decreased normalized MLPA signals (Fig. 1)
is indicated by a yellow bar and the positions of the two MLPA probes
located in exon 1 of FBN1 are denoted by arrows (Wlled triangle). The
regions with loss of heterozygosity and decreased SNP array signal
intensity both gained by the AVymetrix GeneChip Human Mapping
500 K Array Set are indicated by white and blue bars, respectively
(note that the Xanking SNPs are not included in the regions, displaying
an open interval). The positions of SNPs tested in the array set are de-
noted by vertical lines. Note the large region (»67 kb) with loss of het-
erozygosity not associated with the deletion. Primers designed for
long-range PCR (LR primers 44F and 44R) and the deleted region of
the genomic DNA (brown bar) are indicated. b Sequences of the long-
range PCR product spanning the breakpoint junction of the deletion.
Uppercase letters indicate sequences of FBN1 intron 1, lowercase let-
ters denote intergenic sequences. Due to identical sequences at the site
of breakpoints, the break and rejoining could have occurred at three
positions as indicated by arrows (open triangle). The dotted line marks
the most telomeric position of the possible breakpoints. All nucleotide
positions are described in relation to the human genome reference se-
quence (NCBI build 36.1)
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MFS patients. In this context, mutations resulting in func-
tional haploinsuYciency can also be associated with mild
phenotypes which may fail to meet the diagnostic criteria
for MFS (Dietz et al. 1993). However, such association
between mutant transcript abundance and disease severity
could not be found in Patients 44 and 70, similar to previ-
ously reported patients with classic severe MFS who har-
bored very low levels of PTC-containing mutant transcripts
(Halliday et al. 1999).
Taken together, Patient 70, and most likely Patient 44 as
well, have only a single functional FBN1 allele, represent-
ing true haploinsuYciency. Since the Wrst description of an
FBN1 mutation (Dietz et al. 1991), the role of haploinsuY-
ciency in the pathogenesis of MFS has been the subject of
intensive investigations and discussions. Mouse models
suggested a critical threshold of functional microWbrils in
the disease presentation of MFS (Pereira et al. 1999) and
provided evidence for a critical contribution of haploin-
suYciency by showing that half-normal amounts of
Wbrillin-1 can be insuYcient to initiate productive micro-
Wbrillar assembly (Dietz and Mecham 2000; Judge et al.
2004). Furthermore, mouse MFS models showed that mice
Fig. 3 Breakpoint analyses in Patient 70. Symbols and labels are as
used in Fig. 2. a Schematic representation of the genome in the region
of deletion as well as overview of the results of the MLPA and SNP ar-
ray analyses. Note the extended region (»180 kb) with loss of hetero-
zygosity not deleted. Forward and reverse primers designed for long-
range PCR are indicated (LR primers 70F and 70R). For clarity, exons
C, A, and B of FBN1 are not shown (cf. Fig. 2). b Sequences of the
long-range PCR product spanning the breakpoint junction of the dele-
tion. Uppercase letters indicate sequences of FBN1 intron 16, and
lowercase letters denote sequences of CEP152 intron 2
Deletion of 302,580 bp
46,489,479
SNP_A-2167448
rs7359317
47,063,708
46,724,391 46,820,637 46,903,22646,890,519 47,042,933
Decreased SNP array signal intensity
FBN1 CEP152 SHC4
SNP_A-2221556
rs11070644
46,571,789
46,580,456 46,883,035
1 1 13 1225151723 21665
Loss of heterozygosity
SNP_A-2134212
rs2899422
46,888,783
LR primer 70F LR primer 70R
Centromere
50 kb
Decreased MLPA signals
15q21.1
EID1
A
B
15q21.1
T T TTGAATA T T TTCA GTAC T TTAAACA GCC TACCCCa t a a t c a t c a t g t t a g a g t c a a t  t c a g c t a t a t a t c Junction
T T TTGAATA T T TTCA GTAC T TTAAACA GCC TACCCCCCAT TCT TGA A AT GAGGGA TAT CCTACA T TCGGA T G
Reference sequence
46,580,491
a t  t t t t a t t a a c a t g a a g t t  t t t t a c a a a t t t a a c c a t a a t c a t c a t g t t a g a g t c a a t  t c a g c t a t a t a t c 46,883,071
Fig. 4 Partial reverse sequence of the FBN1 3 untranslated region
Xanking the polymorphism c.8,930C > T (g.46,490,165 NCBI build
36.1; arrowed). Note that the cDNA sequence of Patient 70 heterozy-
gous for c.8,930C > T lacks allele C (black) and is indistinguishable
from the cDNA sequence of Control 2 homozygous for allele T
(green), while in the controls the results at gDNA and cDNA levels are
consistent with respect to each other. Complementary DNA sequences
were derived from cultured Wbroblast mRNA stabilized by the transla-
tion inhibitor cycloheximide
Genomic DNA (gDNA) Complementary DNA (cDNA) 
c.[8930T>C]+[=] c.[=]+[=]
Patient 70 Control 1 Control 2 Patient 70 Control 1 Control 2
c.[8930T>C]+[=]
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haploinsuYcient in Wbrillin-1 have marked dysregulation of
transforming growth factor beta (TGF-beta) signaling
(Neptune et al. 2003), most likely due to the fact that Wbril-
lin-1 regulates the bioavailability of TGF-beta 1 (Chaudhry
et al. 2007). In humans, although several observations sup-
ported a traditional dominant-negative mechanism, it has
been suggested that functional haploinsuYciency through
NMD of most of the mutant mRNAs plays a role in the
pathogenic mechanism of MFS (Dietz et al. 1993; Hewett
et al. 1994; Nijbroek et al. 1995; Pepe et al. 2001; Caputi
et al. 2002; Judge and Dietz 2005; Robinson et al. 2006).
However, since mutant transcripts being subject to NMD
are often not completely degraded, it has remained unclear,
whether the potent dominant-negative eVect of the remaining
mutant transcripts leads to the disease. Even cytogenetically
detectable heterozygous deletions of the entire FBN1 gene,
although suggested, failed to demonstrate the role of true
haploinsuYciency in MFS, because these chromosomal
abnormalities aVect not only FBN1 but also several other
genes, resulting in diVerent phenotypes do not meet the
Ghent criteria (e.g., Hutchinson et al. 2003; Adès et al.
2006). Hence, the Wndings in this study demonstrate for the
Wrst time that true haploinsuYciency, i.e., the complete loss
of function of one FBN1 allele, is suYcient to cause MFS in
patients. In such cases, increased expression from the nor-
mal FBN1 allele may represent a novel therapeutic avenue.
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